Boehringer Ingelheim/Pfizer's Spiriva gets FDA panel nod for exacerbations claim
This article was originally published in Scrip
Executive Summary
The US FDA's pulmonary-allergy drugs advisory panel has endorsed adding a claim to Boehringer Ingelheim's long-acting anticholinergic Spiriva HandiHaler (tiotropium bromide; licensed to Pfizer) for reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
You may also be interested in...
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.